Related references
Note: Only part of the references are listed.Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
Raphael E. Steiner et al.
HAEMATOLOGICA (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Matthias Totzeck et al.
EUROPEAN HEART JOURNAL (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
Adam Goldman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction
Cian P. McCarthy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations
Jeremy R. Stone et al.
JCO ONCOLOGY PRACTICE (2021)
Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations
Jeremy R. Stone et al.
JCO ONCOLOGY PRACTICE (2021)
Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors
Sarah Waliany et al.
JACC: CARDIOONCOLOGY (2021)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Cytokine Storm
David C. Fajgenbaum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma
Sarju Ganatra et al.
CIRCULATION (2020)
Cardiovascular Effects of CAR T Cell Therapy A Retrospective Study
Benedicte Lefebvre et al.
JACC: CARDIOONCOLOGY (2020)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart JACC Council Perspectives
Sarju Ganatra et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Raza M. Alvi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Daniela Cardinale et al.
CIRCULATION (2015)
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Daniela Cardinale et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anthracycline-Induced Cardiomyopathy Clinical Relevance and Response to Pharmacologic Therapy
Daniela Cardinale et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)